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Objectives: To investigate the rates and causality of
adverse event(s) (AE) associated with natural health
product (NHP) use, prescription drug use and
concurrent NHP-drug use through active surveillance in
community pharmacies.
Design: Cross-sectional study of screened patients.
Setting: 10 community pharmacies across Alberta
and British Columbia, Canada from 14 January to
30 July 2011.
Participants: The participating pharmacy staff
screened consecutive patients, or agents of patients,
who were dropping or picking up prescription
medications.
Primary outcome measures: Patients were
screened to determine the proportions of them using
prescription drugs and/or NHPs, as well as their
respective AE rates. All AEs reported by the screened
patients who took a NHP, consented to, and were
available for, a detailed telephone interview (14%)
were adjudicated fully to assess for causality.
Results: Over a total of 105 pharmacy weeks and
1118 patients screened, 410 patients reported taking
prescription drugs only (36.7%; 95% CI 33.9% to
39.5%), 37 reported taking NHPs only (3.3%; 95% CI
2.4% to 4.5%) and 657 reported taking prescription
drugs and NHPs concurrently (58.8%; 95% CI 55.9%
to 61.6%). In total, 54 patients reported an AE,
representing 1.2% (95% CI 0.51% to 2.9%), 2.7%
(95% CI 0.4% to 16.9%) and 7.3% (95% CI 5.6% to
9.6%) of each population, respectively. Compared with
patients who reported using prescription drugs, the
patients who reported using prescription drugs and
NHPs concurrently were 6.4 times more likely to
experience an AE (OR; 95% CI 2.52 to 16.17;
p<0.001). Combined with data from Ontario, Canada, a
national proportion was calculated, which found that
45.4% (95% CI 43.8% to 47.0%) of Canadians who
visit community pharmacies take NHPs and
prescription drugs concurrently, and of those, 7.4%
(95% CI 6.3% to 8.8%) report an AE.
Conclusions: A substantial proportion of community
pharmacy patients use prescription drugs and NHPs
concurrently; these patients are at a greater risk of
experiencing an AE. Active surveillance provides a
means of detecting such AEs and collecting high-
quality data on which causality assessment can be
based.
Strengths and limitations of this study
▪ Active surveillance likely detects adverse events
(AEs) due to natural health product (NHP) and
prescription drug use at a higher rate than
passive surveillance alone, the system that is
currently employed by most of the regulatory
agencies around the world.
▪ Patient interviews allowed for meaningful infor-
mation to be collected to allow for full causality
assessment of an AE; laboratory analysis sup-
ported this assessment.
▪ The AE rate in patients taking NHPs and pre-
scription drugs concurrently could be compared
with those taking prescription drugs alone.
▪ The first national data were analysed for this
hypothesis across Canada.
▪ Data in British Columbia are not consistent with
Alberta and Ontario.
▪ Risk for possible biases (recall bias, selection
bias) due to observational study design.
▪ High loss to follow-up rate occurred between the
screening and patient interview phases.
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INTRODUCTION
The use of natural health products (NHPs) is popular
worldwide.1–3 Recent surveys in North America,
Australia and Europe have found that at least half of the
population use NHPs, defined by Health Canada,
Canada’s federal regulatory agency, as any vitamin,
mineral, herbal remedy, homeopathic medicine, trad-
itional medicine, probiotic, amino acid or fatty acid
product.1 4–7 NHPs have become the second most pur-
chased over-the-counter (OTC) product in Canada in
2012, next to headache and pain relief products.2
Reasons for use are multifactorial, including an
increased interest in natural approaches focused on pre-
vention, media advertising and increased concern with
taking synthetic drugs.1 8 Healthcare professionals are
following this trend in their practices as well, with 38%
of physicians now recommending NHPs to their
patients and 89% of pharmacists spending more than
30 min/day counselling on these products.9 10
With increasing NHP use, the concern for consumer
safety is also growing.3 11 12 Typically, NHPs are consid-
ered by users to be safe since they are ‘natural’13;
however, studies demonstrate some serious toxicities and
many possible adverse reactions (ARs) with the use of
these products.3 11–15 Further, NHP use is higher among
patients with chronic medical conditions,16 17 where
prescription drug use is likely: 58% of cardiovascular
patients taking narrow therapeutic index drugs used
NHPs and prescription drugs concurrently,18 compared
with 39.7% of community pharmacy patients screened
in Ontario (ON).19 In patients over 50 years old, 87.4%
of those taking NHPs did so in combination with
drugs.20 Such patients are at greater risk of drug interac-
tions,21 and therefore ARs.
In regulatory agencies worldwide, passive surveillance
systems are employed to detect postmarketing ARs.22
These systems rely on spontaneous reports of suspected
ARs by consumers, health professionals and industry.23
While this type of postmarketing surveillance allows for
the detection of ARs in ‘real-world’ conditions, it
depends on individuals recognising when an adverse
event (AE) should be reported and their knowledge to
submit a high-quality report for interpretation and
assessment.22 23 Of note, an AE becomes an AR when
causation is suspected to be due to a health product.24
An AE encompasses any unfavourable or unintended
sign, symptom or disease associated with the use of a
medicinal product, whether or not considered related to
the product itself.24 It is estimated that only 1–10% of all
AEs are ever captured by passive surveillance systems.23
Detection of AEs associated with NHPs is further com-
plicated by physicians and pharmacists who do not con-
sistently inquire about NHP use during medical
history-taking, and reporting NHP-related AEs less often
than AEs associated with prescription drugs or OTC
drugs.9 25 In addition, many patients choose not to dis-
close NHP use to their healthcare providers, or to report
to them about suspected adverse drug reactions
associated with these products.12 Evidence suggests that
one-third of patients are unaware of any risk associated
with NHPs.26
An alternative system, or one that can be used to com-
plement passive surveillance, is increasingly being identi-
fied as necessary to mitigate the harms to patients.23
Worldwide active surveillance systems, such as the
Sentinel initiative to monitor postmarket risk analysis of
health products in the USA and the National Cancer
Registry in the UK, are proving to be a successful means
of collecting AR data.23 A method of active surveillance
that still appears underutilised, however, is the process of
building AE detection screening into health profes-
sionals’ practice.
Pharmacy study of NHP ARs (SONAR) is a multicentre
population-based observational study in which research-
ers partnered with Health Canada and community
pharmacists and pharmacies to implement an active sur-
veillance screening system to detect AEs associated with
NHPs experienced by patients at this setting.19 A pilot
study in ON, Canada, found that 39.7% of patients were
taking NHPs and prescription drugs concurrently, of
which 7.4% reported an AE.19 This represented at least
a 3000-fold higher rate of ARs than that captured by
Health Canada’s passive surveillance system over a corre-
sponding time period. The Pharmacy SONAR pilot
study was limited, however, by the lack of comparable
data for patients taking prescription drugs or NHPs
alone.19
Pharmacy SONAR was expanded to Alberta (AB) and
British Columbia (BC), Canada, to investigate the rate
of each prescription drug, NHP and concurrent pre-
scription drug-NHP use, and their respective AE rates,
through an active surveillance model in community
pharmacies across Western Canada. Our objective was
to further assess the feasibility of implementing active
surveillance into community pharmacy practices and
to calculate a national proportion of patients using
prescription drugs and NHPs concurrently, as well as the
proportion of those reporting an AE.
METHODS
A two-phase cross-sectional model, as detailed in the ON
pilot study,19 was maintained for the purpose of this
study. Phase I involved the implementation of active sur-
veillance in community pharmacies and data collection
through patient interviews; phase II involved AE causal-
ity assessment and laboratory analysis where appropriate.
Phase I: active surveillance
Community pharmacists volunteered to participate.
In-store training and all relevant study materials, such as
screening logs and patient information packages, were
provided to each community pharmacy site. Each site
received a copy of an authoritative reference text,
Natural Standard27 and a NHP–drug interaction grid28
(created for the pilot study) to support knowledge in
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this area. Staff were provided follow-up and assistance
through remote support (ie, telephone contact), as
compared with in-person support by the ON study19 to
assess for continued feasibility with less intervention.
All consecutive patients bringing prescriptions or col-
lecting medication for themselves (or for a child or other
close family member) at a participating pharmacy were
included in the study. Pharmacists and pharmacy staff
asked such patients three questions on the screening log
(figure 1). The patients unable to communicate in
English were excluded. NHPs were defined in accord-
ance with Health Canada’s definition: any vitamin,
mineral, herbal remedy, homeopathic medicine, trad-
itional medicine, probiotic, amino acid or fatty acid
product.7 One month was chosen as a suitable screening
history period to capture AEs following product use to
minimise recall bias. If the patient answered yes to ques-
tions 2 and 3, they received a study information package.
If the patient agreed to participate in follow-up, written
consent was obtained by a pharmacy staff member and
the study pharmacist was notified. Community pharmacy
staff did not assess causality of any reported AE.
The study pharmacist (CN) conducted a detailed tele-
phone interview with consenting patients within 1 week
of their reporting an AE(s). Verbal consent was obtained
at the start of the interview. The interview comprised
questions detailing medical conditions, all drug and NHP
use and details around the AE(s). The interview form was
adapted from the pilot study to include additional details
of the NHPs (ie, how they were prepared, when relevant).
A copy of the interview form is available from the corre-
sponding author on request. The medical history of
3 months was collected through a telephone interview,
allowing for more extensive data to lend knowledge to
the overall causality assessment. If deemed necessary, the
patient was asked to provide samples of the NHPs and
drugs taken at the time of the AE(s) for laboratory ana-
lysis in phase II and for consent to report the AE(s) to
Health Canada, if this had not already been done.
Phase II: causality assessment and laboratory analysis
All interviewed cases were summarised and adjudicated
by a three-member committee: one clinical NHP expert,
one basic science NHP expert and a committee chair
(SV) knowledgeable in both areas. The two experts inde-
pendently assessed each case based on the WHO
Causality Assessment Criteria,29 the Naranjo Probability
Scale30 and the Horn Drug Interaction Probability
Scale.31 In each instance, consensus was reached
through discussion. Two laboratories were available for
undertaking the following analyses in this study: (1)
NHP constituent assessment and (2) adulteration/con-
tamination assessment. The laboratories tested the
samples provided by the participants, and if the samples
were unavailable, similar products from the same lot or
batch were tested.
Statistical analysis
Phase I data were used to calculate proportions by phar-
macy. A weighted average proportion for each outcome
with the associated 95% CIs were provided using a logis-
tic regression with intercept only model. ORs and the
associated 95% CIs for AE rates for participants using
NHPs only and NHP-prescription drugs concurrently,
compared with prescription drug use only, were calcu-
lated using logistic regression. Stata V.12.0 was used for
all analyses.32
RESULTS
Phase I: active surveillance
Ten pharmacies across AB (n=7) and BC (n=3) partici-
pated in the study. Over a period of 105 pharmacy weeks
(14 January to 30 July 2011), 1118 patients were
screened. Tables 1 and 2 show proportions of patients
screened using NHPs and/or prescription drugs and
those reporting AEs, respectively. The results were
similar when the responders with incomplete screening
data (ie, each of the three questions were not filled in)
were included in the denominator of the analysis; there-
fore, the results are reported including all patients
screened.
When compared with taking prescription drugs alone,
patients taking concurrent NHP-prescription drugs were
6.38 (95% CI 2.52 to 16.17; p<0.001) times more likely
to experience an AE. When looking at AB separately,
the OR was 4.78 (95% CI 1.88 to 12.16; p<0.001); an OR
could not be provided for BC due to having no AE
reports in the exposure reference group (prescription
drugs only). Table 3 provides ORs for each province,
where such analysis was possible. Similarly, data could
not be further stratified by pharmacy due to a lack of AE
reports in the exposure reference group in some phar-
macies. Nearly half (n=17; 34.0%) of the patients report-
ing an AE, while also taking a NHP, consented to be
contacted for a detailed interview, of whom 7 (14.0%)
were interviewed. Four patients reporting an AE with
NHP use were referred to the study for causality assess-
ment. All four patients were interviewed and underwent
phase II of the study; however, they were not included in
the phase I analysis since they were not screened at aFigure 1 Patient screening questions.
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participating study site. Figure 2 details patient involve-
ment during the two study phases.
Phase II: causality assessment and laboratory analysis
Nine of the 11 cases with detailed interviews underwent
causality assessment; 2 were not assessed due to AEs
occurring beyond the 1-month screening timeframe
(figure 2). Two of nine cases (22.2%) were determined
to be ‘likely’ due to a NHP, with one case likely due to
an interaction between one or more NHPs and a pre-
scription drug. A brief summary of each adjudicated
case, as well as patient demographics collected, is
described in table 4. Laboratory analysis was available for
all cases that warranted it, which was determined on a
case-by-case basis. Analyses were performed in three
reported cases (3, 4 and 5) to assess contribution to
causality assessment; significant findings, or lack thereof,
are described in table 4.
DISCUSSION
Principal findings
Implementing active surveillance into community pharma-
cies markedly improves the detection of AEs reported by
patients taking NHPs. The results indicate that adding one
Table 1 Weighted proportions of participants using prescription drugs, NHPs or both, by pharmacy and province
Pharmacy Participants (ni)
Prescription drug





AB01 113 38 (33.6%) 3 (2.6%) 72 (63.7%)
AB02 119 33 (27.7%) 9 (7.6%) 75 (63.0%)
AB03 101 32 (32.0%) 4 (4.0%) 64 (63.4%)
AB04 312 74 (23.7%) 10 (3.2%) 222 (71.2%)
AB05 10 2 (20.0%) 2 (20.0%) 5 (50.0%)
AB06 181 74 (40.9%) 0 (0.0%) 107 (59.1%)
AB07 44 16 (36.4%) 5 (11.4%) 23 (52.3%)
Alberta total 880 270 (30.7%)
(95% CI 27.7 to 33.8)
33 (3.8%)
(95% CI 2.7 to 5.2)
568 (64.6%)
(95% CI 61.3 to 67.6)
BC01 149 104 (69.8%) 3 (2.0%) 37 (24.8%)
BC02 58 33 (56.9%) 0 (0.0%) 25 (43.1%)
BC03 31 3 (9.7%) 1 (3.2%) 27 (87.1%)
British Columbia total 238 140 (58.8%)
(95% CI 52.5 to 64.9)
4 (1.7%)
(95% CI 0.6 to 4.4)
89 (37.4%)
(95% CI 31.4 to 43.7)
Western Canada total 1118 410 (36.7%)
(95% CI 33.9 to 39.5)
37 (3.3%)
(95% CI 2.4 to 4.5)
657 (58.8%)
(95% CI 55.9 to 61.6)
NHPs, natural health products.











AB01 5 0 (0.0%) 0 (0.0%) 5 (6.9%)
AB02 8 1 (3.0%) 1 (11.1%) 6 (8.0%)
AB03 10 2 (6.3%) 0 (0.0%) 8 (12.5%)
AB04 19 1 (1.4%) 0 (0.0%) 8 (8.1%)
AB05 3 0 (0.0%) 0 (0.0%) 3 (60.0%)
AB06 5 0 (0.0%) 0 (0.0%) 5 (4.7%)
AB07 3 1 (6.3%) 0 (0.0%) 2 (8.7%)
Alberta total 53 5 (1.9%)
(95% CI 0.8 to 4.4)
1 (3.0%)
(95% CI 0.4 to 18.6)
47 (8.3%)
(95% CI 6.3 to 10.8)
BC01 0 0 (0.0%) 0 (0.0%) 0 (0.0%)
BC02 1 0 (0.0%) 0 (0.0%) 1 (4.0%)
BC03 0 0 (0.0%) 0 (0.0%) 0 (0.0%)
British Columbia total 1 0 (0.0%) 0 (0.0%) 1 (1.1%)
(95% CI 0.2 to 7.5)
Western Canada total 54 5 (1.2%)
(95% CI 0.51 to 2.9)
1 (2.7%)
(95% CI 0.4 to 16.9)
48 (7.3%)
(95% CI 5.6 to 9.6)
AEs, adverse events; NHPs, natural health products.
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or more NHPs to a patient’s prescription drug regimen sig-
nificantly increases the likelihood of reporting an AE. Our
study’s interview and adjudication process allowed for com-
plete causality assessment of the AEs reported by consent-
ing and interviewed patients, since an AE is not
considered an AR until causality is suspected or con-
firmed, as well as until meaningful, high-quality AR
reports are submitted to Health Canada. The screening
questions trialled were brief33 and well accepted by phar-
macists, allowing full disclosure around NHP use and an
opportunity to discuss health outcomes with their patients.
Strengths of the study
Pharmacy SONAR’s active surveillance detected 54 AE
reports in 1118 patients screened; in comparison,
Health Canada received 342 spontaneous AR reports
involving NHPs during the same time period from a
population of approximately 30 million Canadians.34 It
is arguable whether these data are comparable, as by
definition, AR reports assume a causal relationship by
whomever submits them, while AE requires assessment
to determine causality. While reports submitted to
Health Canada are labelled ARs, they still undergo inde-
pendent assessment by the regulatory agency to assess
causality. Events identified in Pharmacy SONAR were
labelled AEs pending adjudication; however, they were
obtained through specific questioning about product
exposure. We believe that the designation of ‘AR’ should
be reserved until causality assessment has been deter-
mined. Our study was able to ascertain AE reports in






OR (95% CI) p Value OR (95% CI) p Value
Alberta total 1.66 (0.19 to 14.62) 0.650 4.78 (1.88 to 12.16) <0.001
British Columbia total NA – NA –
Western Canada total 2.25 (0.26 to 19.78) 0.465 6.38 (2.52 to 16.17) <0.001
NA, not applicable; NHP, natural health product.
Figure 2 Flow diagram of phase
I and II results. AE, adverse
event; NHP, natural health
product.
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Prescription and over-the-counter drugs
(oral administration unless otherwise
specified)
Natural health products† (brand name,










None; none; Amlodipine, bisoprolol, ezetimibe,
levothyroxine, ramipril, rosuvastatin,
clopidogrel
Flaxseed oil, omega-3 fatty acids, vitamin D,
calcium/magnesium/zinc*
















None; none Sertraline, polyethylene glycol,
metoclopramide, mineral oil, fluticasone
propionate inhalation aerosol
Chinese herbal tea; laboratory analysis detected
camphor





None; none None Ganoderma lucidum/cocoa (Cocozhi)*;
laboratory analysis detected caffeine






None; none Ibuprofen Belladonna/Chamomilla vulgaris/Ferrum
phosphoricum (Camilia—Canadian formulation)*,
Chamomilla/Phytolacca decandra/Rheum
officinale (Camilia—USA formulation)*, Calcium
carbonicum Hahnemanni/Pulsatilla/Chamomilla/
Plantago major/Dulcamara/Belladonna













None Rosemary, honey, witch hazel, fenugreek seed,
black seed, King Solomon seed, ginseng
powder, damiana leaves, marshmallow, sage,
juniper berries, chamomile flowers, cloves,






































*Denotes combination products as indicated by a ‘/’ between ingredients.
†Products and ingredients are as stated on the manufacturers’ product package.
‡Details of case, including all NHPs and their ingredients, have been published elsewhere.49
































specific patient subgroups: those taking prescription
drugs only, NHPs only and both concurrently. Another
strength of our study is the causality assessment that was
available for each AE reported; however, in practical
terms, it was restricted to only those who consented to,
and were available for, an interview. Although schedul-
ing patient interviews was not without challenges, all
that were completed provided meaningful information
to allow for a full adjudication of the AE. Health Canada
could not provide information on how many of their
342 reports involving NHPs were assessed for causality.34
Many important steps need to be taken before a
reported AE associated with a product can be deemed
causal; unfortunately, data collected through passive sur-
veillance systems are often of insufficient quality to
support this process.11 23 24 35 The knowledge gained
through laboratory analysis around constituents and
toxicology of NHPs associated with AEs collected in our
study allowed insight into the causality of the event.
Limitations of the study
Only a fraction of patients visiting participating pharma-
cies was screened in our study; exact information on the
proportion screened is not known since pharmacies
consider the denominator (number of patients seen)
proprietary. Community pharmacists reported time con-
straints due to high prescription volumes and numerous
corporate demands. We attempted weekly phone calls to
improve staff involvement, but limited our support to
that which could be accomplished remotely (ie, off-site).
Seeking pharmacy participation from the store level
rather than the corporate level seemed to improve staff
engagement. Ideally, the screening questions tested in
this study should be built into pharmacists’ routine prac-
tice in order to gain insight into their patients’ health
outcomes and monitor health product (drugs and
NHPs) safety. Given the Canadian population of 30
million people, the relatively few patients screened in
our study do not allow for a definitive conclusion to be
drawn; our results are, however, strongly indicative of the
potential risks present when combining prescription
drug and NHP use.
Biases were also possible given the observational study
design. Sampling bias may have occurred with respect to
whom, or when, pharmacists screened, based on their
workload. Recall bias was minimised limiting the screen-
ing history timeframe to 1 month, encouraging patients
to obtain information from product bottles during the
interview and by confirming information from hospital-
isation records.
The data collected from the pharmacies in BC are not
consistent with that of AB, or even ON.19 Even with
fewer overall patients screened, the AE rates found in
individual pharmacies are much lower than other phar-
macies in AB and ON with similar numbers of patients
screened. Based on discussion with the pharmacy staff,
no clear reasons were provided as to why this may have
occurred. It is possible that the number of patients
screened at those pharmacies was too few to capture a
true AE rate, or there may be important differences in
the number of AEs experienced by patients in this popu-
lation. At the time of screening, pharmacists in BC were
reimbursed by the government to conduct medication
history interviews with their patients; this may have
prevented or resolved AEs occurring in patients
visiting these pharmacies. Further screening is needed
to determine whether this variation found is a true
difference or not.
Our study sampled patients visiting community phar-
macies, who, therefore, are more likely to be taking
prescription drugs, allowing us to sample our target
population of individuals taking NHPs and drugs con-
currently. Macedo et al36 concluded that these patients
might be more likely to experience an AE, since the sim-
ultaneous exposure to three or more drugs significantly
increases the risk of a serious AE. In addition, our study
setting could not capture those patients who are hospita-
lised, due to a serious medical condition or AE, or those
who may have experienced an AE that lead to death.
Given that in any given week, over half of Canadians
aged 18 years and older visit a pharmacy; community
pharmacy was considered to be a suitable study setting
to capture the general population.37
The NHPs listed in table 4 are stated as on the manu-
facturers’ product packages since this is the information
immediately available to someone selling, recommend-
ing or purchasing a NHP; typically, manufacturers’ pack-
aging did not include full product specifications, and
often even basic details, such as plant species and plant
part, were absent.
Study findings in the context of previous research
Results from our study were similar to those collected in
our ON pilot study19; when these data are combined
with those of AB and BC, estimated national proportions
suggest that 45.4% (95% CI 43.8% to 47.0%) of
Canadians who visit community pharmacies take NHPs
and prescription drugs concurrently, and of those, 7.4%
(95% CI 6.3% to 8.8%) report an AE. To our knowl-
edge, no other national data about AEs associated with
concurrent NHP-drug use have been reported previ-
ously. Active surveillance in paediatric populations has
been studied, finding that 48% of patients to be using
complementary and alternative medicine (CAM) and
prescription drugs concurrently and 11% had potential
vitamin and medication interactions.38 39 In patients of
50–64 years old, 14.2% were at risk of a potential NHP–
drug interaction; this proportion increased to 23.7%
and 38.4% in those taking 5 or more and 10 or more
health products concurrently, respectively.21
When looking at NHP safety, other active surveillance
systems such as national and provincial drug and disease
registries or databases are limited, as most of them lack
the ability to record NHP and OTC product use.23 40 In
addition, many of these registries and databases focus
on chronic medical conditions, such as cancer or
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rheumatoid arthritis,23 and the general population is
not targeted. Menniti-Ippolito et al41 found that active
surveillance increased AE reporting from 4 to 15.1 in
100 000 children screened. Similarly, AE reporting in a
CAM-specialised primary care setting improved by 148%
when active surveillance was implemented.42
Our study results provide similar data to a recent
national Health Canada survey, where 73% of Canadians
report taking at least one NHP and 15% experienced an
unwanted reaction.1 However, we were able to capture
more specific data (ie, how many of those patients were
taking a NHP with a prescription drug vs alone) and we
identified a markedly higher number of AE reports than
Health Canada.1 It can be argued that the type of events
reported through spontaneous reporting is already sus-
pected to be causally linked to a health product by the
reporter, and would therefore be viewed as an AR
instead of an AE. It is possible that Pharmacy SONAR
captured a higher number of harms due to screening
for all AEs, with or without suspicion of causation.
However, it is also possible that the first two questions in
the screening process may have prompted a patient to
link an event to a health product (asking about product
use before asking about an AE). In addition, the phar-
macy staff may have selectively recorded certain AEs over
others based on their own knowledge or bias around
whether a causal link was plausible.
A survey conducted by Salvo et al43 in southern Italy
found that women aged between 18 and 52 years who
reported an adverse drug event (ADE) were significantly
more likely to be using alternative or complementary
medicine than those who reported no ADE (20.4% and
8.2%, respectively). This survey also collected data on
drug use; however, details around how drugs and com-
plementary medicines were taken (alone or in combin-
ation) were not described.43 Our study was able to
collect such data and, as such, determine whether
patients taking both types of products in combination
are more likely to experience an AE than those taking
drugs alone.
It is likely that there exists a continuum between food,
or dietary compounds, NHPs and drugs, and clinically
relevant interactions exist along this spectrum. Studies
in the literature report such interactions44–48 and
further research will likely continue in this area. The
data collected in our study involved drug use and NHP
use; however, further information was collected on
dietary intake during the telephone interview, especially
when food or beverages were taken at the same time as
NHPs and/or drugs, and considered by the adjudication
committee when assessing for causality.
Implications for policy, research and clinical practice
While passive surveillance systems play an important role
in pharmacovigilance, the use of current active surveil-
lance models should be used to complement these
systems.22 23
Health professionals are encouraged to screen for NHP
use and AEs associated with NHP and prescription drug
during routine patient care. By improving the rates of AE
identification and reporting, possible harms can be
detected sooner, and even prevented. Our study screening
questions are brief, taking approximately 15 seconds per
patient to administer.19 Health professional prompting will
increase the discussion around NHPs with their patients as
well as improve awareness of the therapies their patients
are engaged in so as to improve safety and health out-
comes. It is also important for clinicians to consider that
there is a continuum from food–functional foods–nutra-
ceuticals–NHPs–OTCs–prescription drugs, and they
should be vigilant in collecting a complete medical history
from patients around all products taken and any dietary
modifications made by patients for the purpose of health.
The data collected during this study will be populated
in a database to allow for health professional and
researcher access to NHPs, prescription drugs and com-
binations that have been used with and without reported
AEs, as well as details around specific AEs found. The
data collected around which prescription drugs and
NHPs were taken with and without reports of harm
would be valuable to analyse, and would be important to
patient safety in the future.
CONCLUSIONS
Pharmacy SONAR demonstrates that active surveillance
of prescription drug and NHP-related AEs in community
pharmacies is feasible and increases the rate of AE
detection significantly compared with that of passive sur-
veillance. With methods refined in our pilot study,19 we
have been able to determine national estimates for NHP,
drug and concurrent NHP-drug use and associated AEs.
Of particular note, one of the strongest aspects of this
study is its ability to assess each case reported for causal-
ity, to include laboratory analysis of products and
produce high-quality suspected AR reports for the
federal regulatory body (in this case, Health Canada).
Future research might include assessing the impact of
implementation of active surveillance of NHPs in differ-
ent healthcare locations, such as hospitals or naturo-
pathic clinics. In addition, it would be valuable to screen
patients with chronic medical conditions who may be at
higher risk for experiencing AEs. In terms of the
study process, methods to improve the number of
patients screened and those interviewed after reporting
an AE (loss to follow-up) would allow for a more
definitive conclusion to be drawn and more data col-
lected in this area.
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